StatBite: FDA oncology drug product approvals in 2009.
D000284:Administration, Oral; D000630:Aminopterin / Q000031:analogs & derivatives; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000068818:Cetuximab; D047630:Depsipeptides; D017277:Drug Approval; D000068338:Everolimus; D052203:Ferrosoferric Oxide; D005971:Glutamates; D006147:Guanine / Q000031:analogs & derivatives; D006801:Humans; D007191:Indazoles; D007267:Injections; D000077544:Panitumumab; D000068437:Pemetrexed; D011743:Pyrimidines; D020123:Sirolimus / Q000031:analogs & derivatives; D013449:Sulfonamides; D014481:United States; D014486:United States Food and Drug Administration
C418863:10-propargyl-10-deazaaminopterin; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047630:Depsipeptides; D005971:Glutamates; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; D000068437:Pemetrexed; D000068258:Bevacizumab; D006147:Guanine; D000077544:Panitumumab; C516667:pazopanib; D000068338:Everolimus; C087123:romidepsin; D000630:Aminopterin; C527517:ofatumumab; D000068818:Cetuximab; D020123:Sirolimus; D052203:Ferrosoferric Oxide